Adverum Biotechnologies Inc (ADVM)
6.94
+0.33
(+4.99%)
USD |
NASDAQ |
Sep 27, 16:00
6.96
+0.02
(+0.29%)
After-Hours: 20:00
Adverum Biotechnologies Total Liabilities (Quarterly): 85.77M for June 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 85.77M |
| March 31, 2024 | 85.54M |
| December 31, 2023 | 89.54M |
| September 30, 2023 | 94.06M |
| June 30, 2023 | 110.27M |
| March 31, 2023 | 117.82M |
| December 31, 2022 | 126.85M |
| September 30, 2022 | 124.02M |
| June 30, 2022 | 130.83M |
| March 31, 2022 | 124.44M |
| December 31, 2021 | 123.54M |
| September 30, 2021 | 144.58M |
| June 30, 2021 | 147.00M |
| March 31, 2021 | 46.73M |
| December 31, 2020 | 48.22M |
| September 30, 2020 | 43.00M |
| June 30, 2020 | 48.61M |
| March 31, 2020 | 44.65M |
| December 31, 2019 | 47.77M |
| September 30, 2019 | 41.31M |
| June 30, 2019 | 32.14M |
| March 31, 2019 | 32.90M |
| Date | Value |
|---|---|
| December 31, 2018 | 12.33M |
| September 30, 2018 | 10.35M |
| June 30, 2018 | 13.14M |
| March 31, 2018 | 11.12M |
| December 31, 2017 | 17.88M |
| September 30, 2017 | 17.22M |
| June 30, 2017 | 16.40M |
| March 31, 2017 | 20.55M |
| December 31, 2016 | 18.98M |
| September 30, 2016 | 20.34M |
| June 30, 2016 | 16.69M |
| March 31, 2016 | 11.37M |
| December 31, 2015 | 11.73M |
| September 30, 2015 | 11.50M |
| June 30, 2015 | 13.09M |
| March 31, 2015 | 13.01M |
| December 31, 2014 | 12.42M |
| September 30, 2014 | 11.50M |
| June 30, 2014 | 11.75M |
| March 31, 2014 | 1.699M |
| December 31, 2013 | 1.303M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
41.31M
Minimum
Sep 2019
147.00M
Maximum
Jun 2021
91.23M
Average
91.80M
Median
Total Liabilities (Quarterly) Benchmarks
| EyePoint Pharmaceuticals Inc | 95.94M |
| Cassava Sciences Inc | 54.59M |
| Regenxbio Inc | 221.11M |
| Editas Medicine Inc | 152.79M |
| Apellis Pharmaceuticals Inc | 640.16M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 253.80M |
| Shareholders Equity (Quarterly) | 168.03M |